John S. Lazo

17.1k citations

323 papers · 13.5k indexed · 3 hit papers · h-index 61

Impact in

Toxicology top 0.1%
- Bioactive Compounds and Antitumor Agents
Molecular Biology top 0.5%
- Protein Tyrosine Phosphatases
- Ubiquitin and proteasome pathways
- Cancer therapeutics and mechanisms

Papers in

Toxicology 31
- Bioactive Compounds and Antitumor Agents 31
Molecular Biology 204
- Protein Tyrosine Phosphatases 69
- Cancer therapeutics and mechanisms 26
- Protein Kinase Regulation and GTPase Signaling 25
- Ubiquitin and proteasome pathways 24

Co-authors: Peter Wipf Alan C. Sartorelli Elizabeth R. Sharlow Beverly A. Teicher Dale G. Hoyt Bruce R. Pitt Andreas Vogt Alakananda Basu
Journals: Journal of Pharmacology and Experimental Therapeutics (24 papers)Molecular Pharmacology (15 papers)Journal of Biological Chemistry (14 papers)Assay and Drug Development Technologies (13 papers)Biochemistry (11 papers)
Partner nations: United States Japan Canada

In The Last Decade

John S. Lazo

320 papers receiving 13.2k citations

Hit Papers

align trajectories log scale

Overexpression of Metallothionein Confers Resistance to Anticancer Drugs 1988 · 524 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1988 Science
1981 PubMed
1981 Medical Entomology and Zoology

Peers

Countries citing papers authored by John S. Lazo

Since Specialization

Citations

This map shows the geographic impact of John S. Lazo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John S. Lazo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John S. Lazo more than expected).

Fields of papers citing papers by John S. Lazo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John S. Lazo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John S. Lazo. The network helps show where John S. Lazo may publish in the future.

Co-authors

The 25 scholars most cited alongside John S. Lazo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John S. Lazo Line = papers co-authored together John S. Lazo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Disruption of Ovarian Cancer STAT3 and p38 Signaling with a Small-Molecule Inhibitor of PTP4A3 Phosphatase Journal of Pharmacology and Experimental Therapeutics ·John S. Lazo, Ю Хюслер, 英輔守永, Danielle C. Llaneza, Chao Deng, Peter Wipf, Elizabeth R. Sharlow	2023	7
2	The Promise and Perils of Compound Discovery Screening with Inducible Pluripotent Cell-Derived Neurons Assay and Drug Development Technologies ·Elizabeth R. Sharlow, M. Murat Köseoğlu, George S. Bloom, John S. Lazo	2019	2
3	Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells Assay and Drug Development Technologies ·Paul A. Johnston, Minh M. Nguyen, Javid A. Dar, Junkui Ai, Yujuan Wang, Khalid Z. Masoodi, Tongying Shun, Sunita Shinde, Daniel P. Camarco, Yun Hua, Donna M. Huryn, Gabriela Mustata Wilson, John S. Lazo, Joel B. Nelson, Peter Wipf, Zhou Wang	2016	24
4	High-Content pSTAT3/1 Imaging Assays to Screen for Selective Inhibitors of STAT3 Pathway Activation in Head and Neck Cancer Cell Lines Assay and Drug Development Technologies ·Paul A. Johnston, Malabika Sen, Yun Hua, Daniel P. Camarco, Tong Ying Shun, John S. Lazo, Jennifer R. Grandis	2013	28
5	Targeting Subcellular Localization through the Polo-Box Domain: Non-ATP Competitive Inhibitors Recapitulate a PLK1 Phenotype Molecular Cancer Therapeutics ·Campbell McInnes, CRAIG LANDWEHR, M. Takenaka, Zhengguan Yang, Marko Horvatek, Paul A. Johnston, John S. Lazo, Jianjun Wang, Michael D. Wyatt	2012	18
6	Alkylation Sensitivity Screens Reveal a Conserved Cross-species Functionome Molecular Cancer Research ·David Svilar, Madhu Dyavaiah, Ashley R. Brown, Jiang-bo Tang, Jianfeng Li, Peter R. McDonald, Tong Ying Shun, Andrea Braganza, Xiaohong Wang, Salony Maniar, Claudette M. St. Croix, John S. Lazo, Ian F. Pollack, Thomas J. Begley, Robert W. Sobol	2012	33
7	Development and Validation of a High-Content Screening Assay to Identify Inhibitors of Cytoplasmic Dynein-Mediated Transport of Glucocorticoid Receptor to the Nucleus Assay and Drug Development Technologies ·Paul A. Johnston, Sunita N. Shinde, Yun Hua, Tong Ying Shun, John S. Lazo, Billy W. Day	2012	21
8	A Simplified Synthesis of Novel Dictyostatin Analogues with In Vitro Activity against Epothilone B–Resistant Cells and Antiangiogenic Activity in Zebrafish Embryos Molecular Cancer Therapeutics ·Laura L. Vollmer, M. J. Jiménez, Daniel P. Camarco, Laura Araldi, Hikmat N. Daghestani, Raghavan Balachandran, Miki Satou, John S. Lazo, Neil A. Hukriede, Dennis P. Curran, Billy W. Day, Andreas Vogt	2011	21
9	Profiling the NIH Small Molecule Repository for Compounds That Generate H ₂ O ₂ by Redox Cycling in Reducing Environments Assay and Drug Development Technologies ·Vinodh Krsna, Nicole L. Blackmon, Tong Ying Shun, Sunita N. Shinde, Byeongyeon Lim, Peter Wipf, John S. Lazo, Paul A. Johnston	2010	91
10	microRNA-21 Negatively Regulates Cdc25A and Cell Cycle Progression in Colon Cancer Cells Cancer Research ·Peng Wang, Fangdong Zou, Xiaodong Zhang, Hua Li, Austin Dulak, Robert J. Tomko, John S. Lazo, Zhenghe Wang, Lin Zhang, Jian Yu	2009	261
11	Multimodal Control of Cdc25A by Nitrosative Stress Cancer Research ·Robert J. Tomko, John S. Lazo	2008	17
12	Development of a 384-Well Colorimetric Assay to Quantify Hydrogen Peroxide Generated by the Redox Cycling of Compounds in the Presence of Reducing Agents Assay and Drug Development Technologies ·Paul A. Johnston, Vinodh Krsna, Sunita N. Shinde, Caleb Foster, Tong Ying Shun, Byeongyeon Lim, Peter Wipf, John S. Lazo	2008	96
13	Cell Division Cycle 25B Phosphatase Is Essential for Benzo( a )Pyrene-7,8-Diol-9,10-Epoxide–Induced Neoplastic Transformation Cancer Research ·Sanjay Srivastava, Postoian Tatiana, Tetsuya Oguri, John S. Lazo, Shivendra V. Singh	2007	3
14	Improved low molecular weight Myc-Max inhibitors Molecular Cancer Therapeutics ·Huabo Wang, Dalia I. Hammoudeh, Ariele Viacava Follis, Brian E. Reese, John S. Lazo, Steven J. Metallo, Edward V. Prochownik	2007	168
15	Induction of Cdc25B Regulates Cell Cycle Resumption after Genotoxic Stress Cancer Research ·Postoian Tatiana, John S. Lazo	2007	34
16	Development and Implementation of a 384-Well Homogeneous Fluorescence Intensity High-Throughput Screening Assay to Identify Mitogen-Activated Protein Kinase Phosphatase-1 Dual-Specificity Protein Phosphatase Inhibitors Assay and Drug Development Technologies ·Paul A. Johnston, Caleb Foster, Tong Ying Shun, John Skoko, Sunita Shinde, Peter Wipf, John S. Lazo	2007	33
17	HTS Identifies Novel and Specific Uncompetitive Inhibitors of the Two-Component NS2B-NS3 Proteinase of West Nile Virus Assay and Drug Development Technologies ·Paul A. Johnston, Jennifer Phillips, Tong Ying Shun, Sunita Shinde, John S. Lazo, Donna M. Huryn, Michael C. Myers, Boris I. Ratnikov, Jeffrey W. Smith, Ying Su, Russell Dahl, Nicholas D. P. Cosford, Sergey A. Shiryaev, Alex Y. Strongin	2007	85
18	Development and Implementation of a Miniaturized High-Throughput Time-Resolved Fluorescence Energy Transfer Assay to Identify Small Molecule Inhibitors of Polo-Like Kinase 1 Assay and Drug Development Technologies ·Elizabeth R. Sharlow, Stephanie Leimgruber, Tong Ying Shun, John S. Lazo	2007	10
19	Systems Cell Biology Knowledge Created from High Content Screening Assay and Drug Development Technologies ·Kenneth A. Giuliano, Wing S. Cheung, Dennis P. Curran, Billy W. Day, Andrew J. Kassick, John S. Lazo, Scott G. Nelson, Youseung Shin, D. Lansing Taylor	2005	32
20	Bleomycin inhibition of angiotensin-converting enzyme activity from serum, lungs, and cultured pulmonary artery endothelial cells. PubMed ·John S. Lazo, Thomas J. Lynch, KIFORDU ANYIBUOFU	1986	16

About John S. Lazo

John S. Lazo is a scholar working on Toxicology, Molecular Biology, Oncology, Nutrition and Dietetics and Biotechnology, having authored 323 papers that have together received 13.5k indexed citations. Recurring topics across this work include Protein Tyrosine Phosphatases (69 papers), Bioactive Compounds and Antitumor Agents (31 papers), Trace Elements in Health (28 papers), Cancer therapeutics and mechanisms (26 papers), Protein Kinase Regulation and GTPase Signaling (25 papers), Ubiquitin and proteasome pathways (24 papers), Cancer-related Molecular Pathways (18 papers) and Peptidase Inhibition and Analysis (18 papers). The work is most often cited by research in Toxicology (662 citations), Molecular Biology (7.9k citations), Oncology (2.9k citations), Nutrition and Dietetics (1.5k citations) and Cancer Research (1.4k citations). John S. Lazo has collaborated with scholars based in United States, Japan and Canada. Frequent co-authors include Peter Wipf, Alan C. Sartorelli, Elizabeth R. Sharlow, Beverly A. Teicher, Dale G. Hoyt, Bruce R. Pitt, Andreas Vogt, Alakananda Basu, Edward V. Prochownik and Iliya Lefterov. Their work appears in journals such as Journal of Pharmacology and Experimental Therapeutics, Molecular Pharmacology, Journal of Biological Chemistry, Assay and Drug Development Technologies and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact